Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Heather M Schroeder"'
Publikováno v:
BMC Public Health, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Measures of forced intercourse from the U.S. National Center for Health Statistics (NCHS) indicate high prevalence among U.S. women, which is likely to produce unintended pregnancies. However, NCHS did not measure forced intercour
Externí odkaz:
https://doaj.org/article/714145d739ac4d09a91a5ea73a2dd6d5
Autor:
Christopher Loiselle, Joseph D. Khoury, Yesid Alvarado, Tapan M. Kadia, Hagop M. Kantarjian, Nitin Jain, Heather M Schroeder, Nicholas J. Short, Alessandra Ferrajoli, Sa A. Wang, Farhad Ravandi, Xuelin Huang, Jeffrey L. Jorgensen, Shilpa Paul, Susan O'Brien, Musa Yilmaz, Philip A. Thompson, Guillermo Garcia-Manero, Benjamin Nwakanme, Rebecca Garris, Elias Jabbour, Steven M. Kornblau, Marina Konopleva, Monica Kwari
Publikováno v:
Blood. 136:9-11
Background: For patients (pts) with Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL), combination chemotherapy achieves complete remission rates of 80-90%; however, many pts ultimately relapse, leading to a cure rate of
Autor:
Koji Sasaki, Maria Khouri, Kiyomi Morita, Partow Kebriaei, Joseph D. Khoury, Sa Wang, Marina Konopleva, Guillermo Garcia-Manero, Susan O'Brien, Farhad Ravandi, Jeffrey L. Jorgensen, Richard E. Champlin, Nitin Jain, Rebecca Garris, Elias Jabbour, Issa F. Khouri, Koichi Takahashi, Hagop M. Kantarjian, Heather M Schroeder, Nicholas J. Short
Publikováno v:
CancerReferences. 127(18)
Background The outcome of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone plus ofatumumab hyper-CVAD + ofatumumab (hyper-CVAD + ofatumumab) has not been compared with the outcome of hyperfractionated cyclophosphamide,
Autor:
Tapan M. Kadia, Heather M Schroeder, Nicholas J. Short, Naval Daver, Susan O'Brien, Yesid Alvarado, Richard E. Champlin, Guillaume Richard-Carpentier, Partow Kebriaei, Koji Sasaki, Koichi Takahashi, Ghayas C. Issa, Xuelin Huang, Zhaohui Gu, Keyur P. Patel, Joseph D. Khoury, Maria Khouri, Srdan Verstovsek, Elias Jabbour, Charles G. Mullighan, Issa F. Khouri, Marina Konopleva, Naveen Pemmaraju, Guillermo Garcia-Manero, Hagop M. Kantarjian, Farhad Ravandi, Feng Wang, Jeffrey L. Jorgensen, Nitin Jain, Sa Wang, Courtney D. DiNardo, Yuya Sasaki, Kathryn G. Roberts
Publikováno v:
The Lancet. Haematology. 7(7)
Summary Background The addition of rituximab to intensive chemotherapy improves outcomes in patients with B-cell acute lymphoblastic leukaemia. Ofatumumab is an anti-CD20 monoclonal antibody that binds to the small extracellular loop of CD20 and has
Autor:
Guillermo Garcia-Manero, Heather M Schroeder, Nitin Jain, Nicholas J. Short, Alessandra Ferrajoli, Musa Yilmaz, Glenda Banks, Sa A. Wang, Elias Jabbour, Steven M. Kornblau, Marina Konopleva, Joseph D. Khoury, Philip A. Thompson, Farhad Ravandi, Jeffrey L. Jorgensen, Anna Milton, Xuelin Huang, Juan Rivera, Hagop M. Kantarjian, Tapan M. Kadia, Yesid Alvarado, Rebecca Garris
Publikováno v:
Blood. 138:1233-1233
Background: Blinatumomab is highly effective therapy for both the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and persistent or recurrent measurable residual disease (MRD) after initial ALL therapy. We hypothesized that
Autor:
Tapan M. Kadia, Kiyomi Morita, Guillaume Richard-Carpentier, Ghayas C. Issa, Koichi Takahashi, Maria Khouri, Srdan Verstovsek, Nitin Jain, Koji Sasaki, Guillermo Garcia-Manero, Xuelin Huang, Naval Daver, Courtney D. DiNardo, Yesid Alvarado, Hagop M. Kantarjian, Partow Kebriaei, Jeffrey L. Jorgensen, Bouthaina S. Dabaja, Farhad Ravandi, Sa A. Wang, Susan O'Brien, Issa F. Khouri, Marina Konopleva, Joseph D. Khoury, Heather M Schroeder, Nicholas J. Short, Elias Jabbour, Richard E. Champlin, Naveen Pemmaraju
Publikováno v:
Blood. 136:42-43
Introduction: Outcome of patients (pts) with CD20-positive B-cell acute lymphoblastic leukemia (B-ALL) has significantly improved with hyper-CVAD (HCVAD) in combination with rituximab with 3-year OS 65% (Thomas et al Blood 2009). Ofatumumab is an ant
Autor:
Monica Kwari, Nicole Volter, Guillaume Richard-Carpentier, Guillermo Montalban Bravo, Rebecca Garris, Koji Sasaki, Marina Konopleva, William G. Wierda, Nitin Jain, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Koichi Takahashi, Alessandra Ferrajoli, Heather M Schroeder, Nicholas J. Short, Hagop M. Kantarjian, Jorge E. Cortes, Christopher Loiselle
Publikováno v:
Blood. 134:3807-3807
Background: In adults with B-ALL, multi-agent combination chemotherapy produce high complete remission (CR) rates of 80-90%, but a significant proportion of patients relapse and the long-term cure rate is 40-50%. Monoclonal antibodies have improved s
Autor:
Guillaume Richard-Carpentier, Srdan Verstovsek, Mike Jones, Courtney D. DiNardo, Monica Kwari, Keyur P. Patel, Tapan M. Kadia, Farhad Ravandi, Zhaohui Gu, Marina Konopleva, Nitin Jain, Elias Jabbour, Rebecca Garris, Koji Sasaki, Guillermo Garcia-Manero, Susan O'Brien, Heather M Schroeder, Nicholas J. Short, Kathryn G. Roberts, Christopher Loiselle, Rita Khouri, Hagop M. Kantarjian, Jorge E. Cortes, Ghayas C. Issa, Charles G. Mullighan, Naval Daver
Publikováno v:
Blood. 134:2577-2577
Background: The Hyper-CVAD regimen is safe and effective in the frontline treatment of B-ALL. The addition of rituximab to the Hyper-CVAD regimen (HCVAD-R) improved the 3-year overall survival (OS) to 60% in pts with B-ALL. Ofatumumab is an anti-CD20
Publikováno v:
World Sustainability Series ISBN: 9783319671215
The Sustainability Cultural Indicators Program (SCIP) at the University of Michigan is designed to measure and track the university’s progress (Callewaert and Marans 2017) in moving the campus community towards a culture of sustainability. SCIP gat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6b877d600d1ca2e842fefb6437b8afb
https://doi.org/10.1007/978-3-319-67122-2_21
https://doi.org/10.1007/978-3-319-67122-2_21
Autor:
Murray B. Stein, Heather M. Schroeder, Steven G. Heeringa, Lisa J. Colpe, James Wagner, Andrew D. Piskorowski, Robert J. Ursano
Publikováno v:
Social science computer review. 35(2)
Mixed-mode surveys need to determine a number of design parameters that may have a strong influence on costs and errors. In a sequential mixed-mode design with web followed by telephone, one of these decisions is when to switch modes. The web mode is